Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Følelses- og symptomfokuseret engagementsforsøg for personer med akut leukæmi (EASE)

10. november 2026 opdateret af: Canadian Cancer Trials Group

Følelser og symptomfokuseret engagement (EASE): Et randomiseret kontrolleret forsøg på flere steder af en intervention for personer med akut leukæmi

The purpose of this study is to find out whether a novel manualized intervention, called Emotion and Symptom-focused Engagement (EASE), that combines psychological support with symptom screening plus triggered referral to early palliative care for symptom control, reduces psychological distress and physical symptom burden in individuals newly diagnosed with acute leukemia. To do this, half of the participants in this study will receive the usual care offered to patients with acute leukemia and half of the participants will receive usual care plus the EASE intervention.

Studieoversigt

Status

Rekruttering

Betingelser

Detaljeret beskrivelse

The standard or usual care treatment for patients with newly diagnosed acute leukemia involves admission to hospital for treatment (e.g. induction chemotherapy). Additional support services may be delivered if requested or if a doctor thinks it is necessary.

Little research has been done looking at the psychological and physical consequences of being diagnosed with and treated for acute leukemia, but our research team has found that a significant number of these individuals experience symptoms of traumatic stress and severe physical symptoms. Even less research has been done looking at ways to help alleviate this psychological and physical distress. Emotion and Symptom-focused Engagement (EASE) is an integrated psychosocial and early palliative care (symptom control) intervention designed to reduce psychological distress and physical symptom burden in patients newly diagnosed with acute leukemia. The EASE intervention provides i) tailored supportive psychotherapy (called EASE-psy) during the initial weeks of treatment to reduce symptoms of traumatic stress, and ii) symptom screening during the initial inpatient treatment period with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms (called EASE-phys).

A phase II trial of EASE in patients with newly diagnosed acute leukemia demonstrated feasibility and preliminary evidence that it reduces psychological distress and physical symptom severity compared to usual care. This new trial is a definitive phase III, multi-site randomized controlled trial to test the effectiveness of EASE at reducing psychological distress and physical burden.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

196

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • New Brunswick
      • Saint John, New Brunswick, Canada, E2L 4L2
        • Rekruttering
        • Regional Health Authority B, Zone 2
        • Kontakt:
          • Alfonso Rivera Duarte
          • Telefonnummer: 506 648-7109
    • Ontario
      • Hamilton, Ontario, Canada, L8V 5C2
        • Rekruttering
        • Juravinski Cancer Centre at Hamilton Health Sciences
        • Kontakt:
          • Alejandro Garcia-Horton
      • Kingston, Ontario, Canada, K7L 2V7
        • Rekruttering
        • Kingston Health Sciences Centre
        • Kontakt:
          • Annette Hay
          • Telefonnummer: 77094 613 533-6430
      • Ottawa, Ontario, Canada, K1H 8L6
        • Rekruttering
        • Ottawa Hospital Research Institute
        • Kontakt:
          • Pierre Villeneuve
          • Telefonnummer: 613
      • Toronto, Ontario, Canada, M5G 2M9
        • Rekruttering
        • University Health Network
        • Kontakt:
          • Gary Rodin
          • Telefonnummer: 416 946-4504
      • Toronto, Ontario, Canada, M4N 3M5
        • Rekruttering
        • Odette Cancer Centre
        • Kontakt:
          • Lee Mozessohn
          • Telefonnummer: 5847 416 480-5000

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Newly diagnosed AL (acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) chronic myelogenous leukemia (CML) in blast crisis; T-cell leukemia lymphoma (TLL), and AL of ambiguous lineage) and is recruited up to 1 week prior to hospital admission or within 2 weeks of hospital admission. For patients diagnosed with a mixed phenotype AL, the dominant sub-type must be identified for stratification purposes.
  • Receiving or expected to receive induction therapy with curative intent at the time of recruitment.
  • Age ≥ 18 years.
  • Ability to pass the cognitive screening test at the time of recruitment (Short Orientation-Memory-Concentration Test (SOMC) score ≥ 20), unless deemed suitable at the CRA's discretion (e.g. in extenuating circumstances such as interruptions during the administration of the measure or when patients report a learning disability that can influence the results).
  • Patient is fluent in English and is able (i.e. sufficiently literate and competent) and willing to complete the baseline questionnaires in English. Ability but unwillingness to complete the baseline questionnaires will make the patient ineligible.

Exclusion Criteria:

  • Major communication difficulties at the time of recruitment, as assessed by the research team (e.g. severe hearing impairment or inability to speak).
  • Receiving on-site (in hospital) psychological/psychiatric counseling at the time of recruitment.
  • Receiving on-site (in hospital) palliative care services at the time of recruitment.
  • A diagnosis of acute promyelocytic leukemia.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Andet: Almindelig pleje

The usual care group will receive usual care of their acute leukemia at their centre but no formal psychological or palliative care intervention as part of this trial

Eksperimentel: Behavioral: Usual Care + EASE Intervention-psy

EASE Intervention = EASE-psy + EASE-phys

All patients randomized to EASE will receive tailored supportive psychotherapy over the initial 8 weeks following the diagnosis of acute leukemia. The psychotherapy will be delivered by trained therapists and combines elements of relational support, affect regulation, and trauma-informed cognitive behavioural therapy (CBT).

-EASE-phys: All patients randomized to EASE will receive weekly symptom screening during the initial inpatient treatment period (typically 4 weeks) with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms based on a philosophy of multidisciplinary care and comprehensive assessment of symptoms.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Assess the effect of the EASE intervention compared to usual care to reduce traumatic stress symptoms using the Stanford Acute Stress Reaction questionnaire (SASRQ)
Tidsramme: 4 weeks

This 30-item measure assesses severity of traumatic stress symptoms over the past four weeks; it has been updated to be Diagnostic and Statistical Manual of Mental Disorders (DSM-5)-concordant [American Psychiatric Association 2013] for acute stress disorder (ASD). Mean severity of traumatic stress symptoms at 4 weeks will be the first primary outcome

4 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Vurder effekten af ​​EASE-interventionen sammenlignet med sædvanlig pleje for at reducere traumatiske stresssymptomer ved hjælp af SASRQ
Tidsramme: 8 uger, 12 uger og 26 uger
8 uger, 12 uger og 26 uger
Vurder effekten af ​​EASE-interventionen til sædvanlig pleje for at reducere fysiske symptomers sværhedsgrad ved hjælp af MSAS
Tidsramme: 8 uger, 12 uger og 26 uger
8 uger, 12 uger og 26 uger
Vurder effekten af ​​EASE-interventionen sammenlignet med sædvanlig pleje på antallet af deltagere, der opfylder kriterierne i overensstemmelse med en diagnose af ASD og tærskel-ASD baseret på DSM-5-kriterier ved hjælp af SASRQ
Tidsramme: 4, 8, 12 og 26 uger
4, 8, 12 og 26 uger
Vurder effekten af ​​EASE-interventionen sammenlignet med sædvanlig pleje på antallet af fysiske symptomer på kræft og den tilhørende symptom-relaterede lidelse målt ved (MSAS)
Tidsramme: 4, 8, 12 og 26 uger
4, 8, 12 og 26 uger
Vurder effekten af ​​EASE-interventionen sammenlignet med sædvanlig pleje på patienttilfredshed med pleje ved hjælp af 16-element FAMCAR-P16
Tidsramme: 4, 8, 12 og 26 uger
4, 8, 12 og 26 uger
10) EQ-5D-5L vil blive brugt til at måle generisk sundhedsstatus, så den kan bruges til at beregne kvalitetsjusterede leveår (QALY) i en økonomisk evaluering, der sammenligner fordelene og omkostningerne ved EASE-interventionen
Tidsramme: 4, 8, 12, 26 og 52 uger
4, 8, 12, 26 og 52 uger
At sammenligne progressionsfri overlevelse mellem behandlingsarme
Tidsramme: 1 år
1 år
Assess the effect of the EASE intervention compared to usual care to reduce physical symptom severity using the Memorial Symptom Assessment Scale (MSAS)
Tidsramme: 4 weeks

This reliable and valid instrument assesses symptom prevalence, severity and distress associated with 26 common physical and 6 psychological symptoms of cancer. Mean physical symptom severity at 4 weeks will be the second primary outcome

4 weeks
Assess the effect of the EASE intervention compared to usual care on Quality of Life using The Functional Assessment of chronic Illness Therapy-Spiritual Well-being Scale
Tidsramme: 4, 8, 12, 26 and 52 weeks

Individual subscales of the FACIT-Sp provide scores for physical, social/family, emotional, functional spiritual well-being

4, 8, 12, 26 and 52 weeks
Assess the effect of the EASE intervention compared to usual care on depressive symptoms using The Patient Health Questionnaire-9 (PHQ-9)
Tidsramme: 4, 8 ,12 and 26 weeks

This valid 9-item measure of depression has been widely used with patients with advanced cancer. Two additional items assessing intent to cause self-harm and interference with daily activities were included in the measure to ensure patients' safety but are not considered for data analysis.

4, 8 ,12 and 26 weeks
Assess the effect of the EASE intervention compared to usual care on pain using the modified Brief Pain Inventory-Sort Form (BPI)
Tidsramme: 4, 8 12 and 26 weeks

The BPI is a widely used measure to rapidly assess the severity of pain and its impact on functioning and will be assessed as part of the secondary outcomes

4, 8 12 and 26 weeks
The modified brief Experiences in Close Relationships Scale (ECR-M16) is an instrument to measure attachment security or the ability to rely on close others for support when distressed.
Tidsramme: Baseline

It provides subscale scores assessing attachment anxiety (i.e. fear of abandonment) and attachment avoidance (i.e. defensive independence). The ECR-M16 will only be administered at baseline in both arms of the study.

Baseline

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studiestol: Gary Rodin, Princess Margaret Hospital, Canada
  • Studiestol: Camilla Zimmerman, Princess Margaret Hospital, Canada

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

6. januar 2022

Primær færdiggørelse (Anslået)

31. december 2026

Studieafslutning (Anslået)

30. juni 2027

Datoer for studieregistrering

Først indsendt

20. december 2019

Først indsendt, der opfyldte QC-kriterier

8. januar 2020

Først opslået (Faktiske)

13. januar 2020

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • SC26

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner